Monitor the PDUFA date of December 30, 2026 for bezuclastinib in NonAdvSM and the upcoming ASCO oral presentation on May 30, 2026. The APEX NDA submission for AdvSM in 1H 2026 is the next major catalyst. The stock is a binary event play on FDA approvals, position accordingly with defined risk.
How the stock moved after the report
NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · May 5 $36.98entry
- T+1 · 7mo ago −3.00%α −4.39% · $35.87
- T+5 · 6mo ago −7.79%α −9.77% · $34.10
- T+20 · 6mo ago −11.41%α −16.37% · $32.76
- T+60 · 4mo ago +11.84%α +9.10% · $41.36
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Cogent Biosciences reported Q1 2026 net loss of $97.4M, wider than the $72.0M loss in Q1 2025, driven by increased R&D and G&A spending ahead of planned bezuclastinib launches. The company ended the quarter with $866.4M in cash, with two NDAs under FDA review and a PDUFA date of December 30, 2026 for NonAdvSM. The wider loss and lack of revenue are consistent with a pre-commercial biotech, but the stock will trade on regulatory catalysts, not quarterly financials.
Key Facts
- Net loss of $97.4M in Q1 2026 vs $72.0M in Q1 2025
- Cash, cash equivalents and marketable securities of $866.4M as of March 31, 2026
- FDA accepted NDA for bezuclastinib in NonAdvSM with PDUFA date of December 30, 2026
- NDA for bezuclastinib in GIST submitted under RTOR program; APEX NDA for AdvSM expected in 1H 2026
- R&D expenses of $75.4M in Q1 2026 vs $63.0M in Q1 2025
- G&A expenses of $28.2M in Q1 2026 vs $11.9M in Q1 2025
- Cash includes $45.7M net proceeds from ATM stock offering
Financial Impact
Net loss widened by $25.4M YoY to $97.4M; cash burn of ~$34.4M in Q1 2026 (excluding $45.7M ATM proceeds)
Risk Factors
- FDA non-approval or delayed review for bezuclastinib NDAs
- Cash burn rate may require additional financing before reaching profitability
- Competitive landscape in KIT-mutant driven diseases
- Clinical trial failures in pipeline candidates
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-205124 |
| Document: cogt-20260505.htm | 0001193125-26-205124 |
| Document: 0001193125-26-205124-index-headers.html | 0001193125-26-205124 |
| Document: 0001193125-26-205124-index.html | 0001193125-26-205124 |
| Document: 0001193125-26-205124.txt | 0001193125-26-205124 |
| 8-K Data (Synthetic) | 0001193125-26-205124 |
Track record
13 reports on COGT
5 of 6 bullish or bearish reports moved the stock their way by T+60. Best: +17.43% at T+20 after the Jun 12, 2026 report. 5 of 6 went positive at some point.
Filters
- Nov 9, 20267d ago Institutional Cluster Neutral 3/10 Entry $33.54 Now $27.44 −18.19% settles Feb 5
- Nov 5, 202611d ago 8-K Neutral 4/10 No price data
- Nov 5, 202611d ago Press Release Neutral 5/10 Entry $31.65 Now $27.44 −13.29% settles Feb 4
- Aug 10, 202614w ago 8-K Neutral 5/10 No price data
- Aug 10, 202614w ago Press Release Neutral 5/10 Entry $41.53 to $31.06 Now $27.44 −33.93% ▼ −25.21% −22.79% vs SPY
- Aug 9, 202614w ago Institutional Cluster Bullish 6/10 Entry $41.53 to $31.06 Now $27.44 −33.93% ▼ −25.21% −22.79% vs SPY
- Jun 12, 202622w ago Press Release Neutral 4/10 Entry $33.10 to $35.28 Now $27.44 −17.10% ▲ +6.59% +3.32% vs SPY
- Jun 12, 202622w ago Press Release Bullish 7/10 Entry $33.10 to $35.28 Now $27.44 −17.10% ▲ +6.59% +3.32% vs SPY
- May 30, 202624w ago Press Release Bullish 8/10 Entry $34.81 to $36.80 Now $27.44 −21.17% ▲ +5.72% +4.49% vs SPY
- May 28, 202624w ago Press Release Bullish 8/10 Entry $35.38 to $36.73 Now $27.44 −22.44% ▲ +3.82% +2.08% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers